10/28/2026
Pharma giants invest billions in psychedelics despite hurdles
Psychedelics like MDMA and psilocybin gain traction amid regulatory challenges.
Topic archive
mental health
50 stories
10/21/2026
Psychedelics and Silicon Valley: A new frontier
Psychedelics shift from counterculture to tech industry darling, reshaping capitalism.
10/21/2026
Enveric Biosciences reports positive preclinical results
Non-hallucinogenic psychiatric candidate shows promise in early trials.
10/19/2026
Danny Malone returns with 'Burning Hills' after ibogaine treatment
Singer-songwriter Danny Malone's new album follows recovery from addiction with ibogaine therapy.
10/10/2026
Navy SEAL's ibogaine experience highlights risks
Shawn Ryan's story underscores the dangers of seeking healing through psychedelics.
9/23/2026
NeuroThera expands U.S. patents for psychedelic therapies
New patents cover LSD, ketamine, ibogaine combinations for mental health.
9/23/2026
Clearmind Medicine files US patents for psychedelic combinations
New patent applications aim to enhance mental health treatments using LSD, ketamine, ibogaine.
9/23/2026
Understanding the psychedelic drug ibogaine
Ibogaine is studied for treating opioid addiction and PTSD.
9/22/2026
Presley Gerber's ibogaine treatment journey before his death
Model Presley Gerber sought ibogaine therapy in Mexico amid addiction struggles.
9/22/2026
Presley Gerber's death details emerge
TMZ reports on circumstances surrounding Presley Gerber's death.
9/22/2026
Presley Gerber's ibogaine treatment before death
Presley Gerber explored ibogaine for addiction treatment months before his passing.
9/22/2026
Presley Gerber's mental health and addiction struggles
Presley Gerber's journey with mental health and substance use highlights ongoing challenges.
9/22/2026
Presley Gerber's death highlights ibogaine treatment
Cindy Crawford's son advocated for ibogaine before his passing.
9/22/2026
Presley Gerber, son of Cindy Crawford, dies at 27
Gerber's death investigated as suspected overdose amid mental health struggles.
9/22/2026
Ibogaine treatment and the case of Presley Gerber
Presley Gerber's use of ibogaine highlights its controversial role in addiction treatment.
9/21/2026
Cindy Crawford's son dies at 27, sister shares struggles
Cindy Crawford's son passes at 27, sister reveals his challenges.
9/21/2026
Presley Gerber's death linked to apparent overdose
Presley Gerber's death highlights ongoing struggles with addiction and mental health.
9/21/2026
Ibogaine treatment not a cure-all, expert warns after Gerber's death
Bryan Hubbard emphasizes ibogaine's role in addiction treatment, not as a miracle solution.
9/21/2026
Ibogaine gains attention for addiction treatment
Psychedelic compound ibogaine draws interest amid regulatory shifts.
9/21/2026
Presley Gerber's ibogaine treatment detailed before tragic death
Cindy Crawford's son shared his ibogaine experience months before passing in rehab.
9/21/2026
Presley Gerber, son of Cindy Crawford, dies at 27
Model and advocate for mental health, Presley Gerber, passed away in a rehab facility.
9/21/2026
Presley Gerber shares addiction treatment journey
The model opens up about his recovery process on social media.
9/21/2026
Presley Gerber's ibogaine treatment in Mexico before death
Model Presley Gerber underwent ibogaine therapy in Cancun months before his passing.
9/21/2026
Atypical psychedelics: clinical insights
Exploring lesser-known psychedelics and their potential therapeutic roles.
9/16/2026
FDA hearing highlights psychedelic drug trial safety
Public feedback sought on psychedelic drugs' therapeutic potential and safety measures.
9/15/2026
Psychedelic therapies: potential and challenges
Exploring the promise and risks of psychedelic treatments in mental health.
9/15/2026
Psychedelic therapies cited by Trump: key insights
Trump's mention of psychedelic therapies sparks renewed interest in their potential applications.
9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
9/8/2026
Ibogaine and the bicameral mind book release highlights growing interest
Jonathan Dickinson's new book explores ibogaine's therapeutic potential amid rising U.S. policy focus.
9/1/2026
Barrow, ASU launch clinical trial for ibogaine in the US
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/27/2026
Psychedelic medicine gains momentum globally
Israel urged to engage in psychedelic research and development.
8/25/2026
Ibogaine research explores postpartum depression
New framework investigates ibogaine's potential in treating postpartum depression.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/21/2026
Ibogaine research gains momentum for PTSD treatment
Trump administration accelerates psychedelic research for veterans' mental health.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Psyence Biomedical welcomes U.S. support for ibogaine
U.S. backing could accelerate ibogaine research for mental health.
8/19/2026
Trump supports psychedelic drugs for veterans' mental health
Former President Trump advocates for psychedelic treatment to aid veterans.
8/19/2026
Psyence Biomedical stock rises 27% on ibogaine research
Market optimism grows as Psyence Biomedical advances ibogaine studies.
8/19/2026
Trump emphasizes ibogaine development, Psyence BioMed reacts
Former President Trump supports ibogaine research, sparking industry response.
8/18/2026
Puerto Rico advances psychedelic therapy research
Governor's order initiates ibogaine, MDMA, and psilocybin study
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.
7/27/2026
Ibogaine treatment provision included in defense bill
New NDAA provision aims to expand ibogaine access for veterans.
7/23/2026
Trump executive order boosts psychedelic therapy research
Order encourages psychedelic research, allocates $50M for state studies.
7/22/2026
Federal agencies advance psychedelic therapy post-Trump order
Trump's 2026 executive order boosts psychedelic research funding and collaboration.
7/19/2026
Psychedelic drugs market sees positive growth signal
Investment interest grows in psychedelics for mental health treatment.
7/17/2026
Ibogaine's long-term brain effects explored
Psychedelics like ibogaine may offer lasting brain changes.
7/16/2026
Texas leaders advocate ibogaine research
Veterans report transformative effects from psychedelic treatment.
7/16/2026
Texas leaders advocate ibogaine research
Veterans report transformative effects from psychedelic therapy.
7/16/2026
Texas leaders advocate for ibogaine research
Veterans share recovery stories, highlighting ibogaine's potential.
7/15/2026
US backs psychedelic therapy research for veterans
Federal support for ibogaine and other psychedelics aims to aid veterans with PTSD.